[go: up one dir, main page]

WO2004004798A3 - Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques - Google Patents

Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques Download PDF

Info

Publication number
WO2004004798A3
WO2004004798A3 PCT/US2003/014428 US0314428W WO2004004798A3 WO 2004004798 A3 WO2004004798 A3 WO 2004004798A3 US 0314428 W US0314428 W US 0314428W WO 2004004798 A3 WO2004004798 A3 WO 2004004798A3
Authority
WO
WIPO (PCT)
Prior art keywords
systemic delivery
therapeutics
methods
products
central airway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/014428
Other languages
English (en)
Other versions
WO2004004798A2 (fr
Inventor
Richard S Blumberg
Wayne I Lencer
Neil E Simister
Alan J Bitonti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Boston Childrens Hospital
Brandeis University
Bioverativ Therapeutics Inc
Original Assignee
Brigham and Womens Hospital Inc
Boston Childrens Hospital
Brandeis University
Syntonix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/021335 external-priority patent/WO2003077834A2/fr
Application filed by Brigham and Womens Hospital Inc, Boston Childrens Hospital, Brandeis University, Syntonix Pharmaceuticals Inc filed Critical Brigham and Womens Hospital Inc
Priority to JP2004519544A priority Critical patent/JP2006513139A/ja
Priority to AU2003232081A priority patent/AU2003232081B2/en
Priority to CA002491129A priority patent/CA2491129A1/fr
Priority to EP03762973A priority patent/EP1539246A4/fr
Publication of WO2004004798A2 publication Critical patent/WO2004004798A2/fr
Publication of WO2004004798A3 publication Critical patent/WO2004004798A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des procédés et des produits destinés à l'administration systémique transépithéliale d'agents thérapeutiques. Plus particulièrement, la présente invention concerne des procédés et des compositions permettant l'administration systémique d'agents thérapeutiques par introduction d'un aérosol contenant des anticorps ou des conjugués d'un agent thérapeutique avec un partenaire de liaison FcRn dans l'épithélium des voies aériennes centrales du poumon. Les procédés et les dispositifs décrits dans cette invention peuvent s'adapter à une large gamme d'agents thérapeutiques parmi lesquels les protéines et les polypeptides, les acides nucléiques, les médicaments, etc. Ces procédés et ces produits présentent l'avantage de ne pas nécessiter d'introduction en profondeur dans le poumon pour permettre l'administration systémique.
PCT/US2003/014428 2002-07-03 2003-05-09 Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques Ceased WO2004004798A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2004519544A JP2006513139A (ja) 2002-07-03 2003-05-09 治療薬の全身性送達のための中央部気道投与
AU2003232081A AU2003232081B2 (en) 2002-07-03 2003-05-09 Central airway administration for systemic delivery of therapeutics
CA002491129A CA2491129A1 (fr) 2002-07-03 2003-05-09 Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques
EP03762973A EP1539246A4 (fr) 2002-07-03 2003-05-09 Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2002/021335 WO2003077834A2 (fr) 2002-03-15 2002-07-03 Apport par les voies aeriennes centrales pour l'administration systemique de medicaments
USPCT/US02/21335 2002-07-03

Publications (2)

Publication Number Publication Date
WO2004004798A2 WO2004004798A2 (fr) 2004-01-15
WO2004004798A3 true WO2004004798A3 (fr) 2004-10-14

Family

ID=30113575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/014428 Ceased WO2004004798A2 (fr) 2002-07-03 2003-05-09 Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques

Country Status (5)

Country Link
EP (1) EP1539246A4 (fr)
JP (1) JP2006513139A (fr)
AU (1) AU2003232081B2 (fr)
CA (1) CA2491129A1 (fr)
WO (1) WO2004004798A2 (fr)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7557190B2 (en) 2005-07-08 2009-07-07 Xencor, Inc. Optimized proteins that target Ep-CAM
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7973136B2 (en) 2005-10-06 2011-07-05 Xencor, Inc. Optimized anti-CD30 antibodies
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US8039592B2 (en) 2002-09-27 2011-10-18 Xencor, Inc. Optimized Fc variants and methods for their generation
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8318907B2 (en) 2004-11-12 2012-11-27 Xencor, Inc. Fc variants with altered binding to FcRn
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8394374B2 (en) 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
US8524867B2 (en) 2006-08-14 2013-09-03 Xencor, Inc. Optimized antibodies that target CD19
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8937158B2 (en) 2003-03-03 2015-01-20 Xencor, Inc. Fc variants with increased affinity for FcγRIIc
US9040041B2 (en) 2005-10-03 2015-05-26 Xencor, Inc. Modified FC molecules
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US9475881B2 (en) 2010-01-19 2016-10-25 Xencor, Inc. Antibody variants with enhanced complement activity
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US11401348B2 (en) 2009-09-02 2022-08-02 Xencor, Inc. Heterodimeric Fc variants
US11566080B2 (en) 2008-09-17 2023-01-31 Xencor, Inc. Compositions and methods for treating IgE-mediated disorders
US11932685B2 (en) 2007-10-31 2024-03-19 Xencor, Inc. Fc variants with altered binding to FcRn
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
ATE497783T1 (de) 2003-05-06 2011-02-15 Syntonix Pharmaceuticals Inc Gerinnungsfaktor vii-fc chimäre proteine zur behandlung von hämostatischen krankheiten
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CN1926237A (zh) * 2004-01-28 2007-03-07 森托尼克斯制药有限公司 用于治疗不育症的异二聚体促卵泡激素－Fc(FSH－Fc)融合蛋白
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
SI2471813T1 (sl) 2004-07-15 2015-03-31 Xencor, Inc. Optimirane Fc variante
US7625564B2 (en) * 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
JP2010533181A (ja) * 2007-07-13 2010-10-21 アボツト・バイオテクノロジー・リミテツド ＴＮＦα阻害剤の肺投与のための方法及び組成物
WO2009012600A1 (fr) 2007-07-26 2009-01-29 Novagen Holding Corporation Protéines de fusion
EP2203180B1 (fr) * 2007-10-22 2012-11-21 Merck Serono S.A. Ifn-bêta unique fusionné à un fragment fc d'igg muté
EP3189831A1 (fr) * 2007-11-30 2017-07-12 AbbVie Biotechnology Ltd Formulations de protéine et leurs procédés de fabrication
CN102492039B (zh) * 2011-11-21 2015-03-11 无锡天演生物技术有限公司 全人源抗人her2单抗
RS62509B1 (sr) 2012-07-13 2021-11-30 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti
AU2014207549B2 (en) 2013-01-15 2018-12-06 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
DK3125942T3 (da) 2014-04-03 2021-12-20 Csl Behring Ag Forstøvning af immunoglobulin
AU2015292326A1 (en) 2014-07-24 2017-02-23 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP3212212B1 (fr) 2014-10-31 2020-09-23 Monash University Formulation de poudre
US20180327768A1 (en) * 2015-11-16 2018-11-15 The Trustees Of The University Of Pennsylvania Targeted delivery of therapeutic proteins bioencapsulated in plant cells to cell types of interest for the treatment of disease
EP4371570A3 (fr) 2016-06-08 2024-07-17 Xencor, Inc. Traitement des maladies associées aux igg4 par des anticorps anti-cd19 se réticulant à cd32b
MA54052A (fr) 2018-10-29 2022-02-09 Hoffmann La Roche Formulation d'anticorps
US12129302B2 (en) 2021-08-25 2024-10-29 Ibio, Inc. Anti-CD-25 antibody

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US20030235536A1 (en) * 2002-03-15 2003-12-25 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8921123D0 (en) * 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
JPH05963A (ja) * 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
DK0805628T3 (da) * 1995-01-17 2003-07-14 Brigham & Womens Hospital Receptor specifik transepitheltransport af immunogener
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
WO2001059142A1 (fr) * 2000-02-09 2001-08-16 Medimmune, Inc. Therapie genique a anticorps avec vecteurs viraux adeno-associes
WO2001074397A1 (fr) * 2000-03-31 2001-10-11 Kirin Beer Kabushiki Kaisha Preparation en poudre destinee a etre administree par les muqueuses comprenant un medicament de forme polymere et presentant une stabilite de conservation amelioree
EP2027874B1 (fr) * 2000-11-28 2013-10-16 Medimmune, Inc. Procédés d'administration/dosage d'anticorps anti-rsv pour la prophylaxie et le traitement
SE0102067D0 (sv) * 2001-06-11 2001-06-11 A & Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US20030235536A1 (en) * 2002-03-15 2003-12-25 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1539246A4 *

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8734791B2 (en) 2002-03-01 2014-05-27 Xencor, Inc. Optimized fc variants and methods for their generation
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US8124731B2 (en) 2002-03-01 2012-02-28 Xencor, Inc. Optimized Fc variants and methods for their generation
US9353187B2 (en) 2002-09-27 2016-05-31 Xencor, Inc. Optimized FC variants and methods for their generation
US8809503B2 (en) 2002-09-27 2014-08-19 Xencor, Inc. Optimized Fc variants and methods for their generation
US8858937B2 (en) 2002-09-27 2014-10-14 Xencor, Inc. Optimized Fc variants and methods for their generation
US8093359B2 (en) 2002-09-27 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US9193798B2 (en) 2002-09-27 2015-11-24 Xencor, Inc. Optimized Fc variants and methods for their generation
US10183999B2 (en) 2002-09-27 2019-01-22 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8039592B2 (en) 2002-09-27 2011-10-18 Xencor, Inc. Optimized Fc variants and methods for their generation
US10184000B2 (en) 2002-09-27 2019-01-22 Xencor, Inc. Optimized Fc variants and methods for their generation
US8383109B2 (en) 2002-09-27 2013-02-26 Xencor, Inc. Optimized Fc variants and methods for their generation
US10113001B2 (en) 2003-03-03 2018-10-30 Xencor, Inc. Fc variants with increased affinity for FcyRIIc
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8937158B2 (en) 2003-03-03 2015-01-20 Xencor, Inc. Fc variants with increased affinity for FcγRIIc
US8735545B2 (en) 2003-03-03 2014-05-27 Xencor, Inc. Fc variants having increased affinity for fcyrllc
US10584176B2 (en) 2003-03-03 2020-03-10 Xencor, Inc. Fc variants with increased affinity for FcγRIIc
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
US8318907B2 (en) 2004-11-12 2012-11-27 Xencor, Inc. Fc variants with altered binding to FcRn
US10336818B2 (en) 2004-11-12 2019-07-02 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8883973B2 (en) 2004-11-12 2014-11-11 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US12215165B2 (en) 2004-11-12 2025-02-04 Xencor, Inc. Fc variants with altered binding to FcRn
US11198739B2 (en) 2004-11-12 2021-12-14 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8852586B2 (en) 2004-11-12 2014-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8324351B2 (en) 2004-11-12 2012-12-04 Xencor, Inc. Fc variants with altered binding to FcRn
US8338574B2 (en) 2004-11-12 2012-12-25 Xencor, Inc. FC variants with altered binding to FCRN
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US9803023B2 (en) 2004-11-12 2017-10-31 Xencor, Inc. Fc variants with altered binding to FcRn
US7557190B2 (en) 2005-07-08 2009-07-07 Xencor, Inc. Optimized proteins that target Ep-CAM
US9040041B2 (en) 2005-10-03 2015-05-26 Xencor, Inc. Modified FC molecules
US9574006B2 (en) 2005-10-06 2017-02-21 Xencor, Inc. Optimized anti-CD30 antibodies
US7973136B2 (en) 2005-10-06 2011-07-05 Xencor, Inc. Optimized anti-CD30 antibodies
US8524867B2 (en) 2006-08-14 2013-09-03 Xencor, Inc. Optimized antibodies that target CD19
US8394374B2 (en) 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
US11932685B2 (en) 2007-10-31 2024-03-19 Xencor, Inc. Fc variants with altered binding to FcRn
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
US11566080B2 (en) 2008-09-17 2023-01-31 Xencor, Inc. Compositions and methods for treating IgE-mediated disorders
US11401348B2 (en) 2009-09-02 2022-08-02 Xencor, Inc. Heterodimeric Fc variants
US9475881B2 (en) 2010-01-19 2016-10-25 Xencor, Inc. Antibody variants with enhanced complement activity

Also Published As

Publication number Publication date
EP1539246A4 (fr) 2007-05-16
WO2004004798A2 (fr) 2004-01-15
AU2003232081B2 (en) 2009-02-05
CA2491129A1 (fr) 2004-01-15
AU2003232081A1 (en) 2004-01-23
JP2006513139A (ja) 2006-04-20
EP1539246A2 (fr) 2005-06-15

Similar Documents

Publication Publication Date Title
WO2004004798A3 (fr) Introduction par les voies aeriennes centrales pour l'administration systemique d'agents therapeutiques
WO2003077834A3 (fr) Apport par les voies aeriennes centrales pour l'administration systemique de medicaments
YU98503A (sh) Pulmonarno ordiniranje hemijski modifikovanog insulina
WO2004019872A3 (fr) Delivrance orale de proteines hybrides modifiees de la transferrine
WO2004082628A3 (fr) Biodisponibilite amelioree et administration amelioree de medicaments acides pharmaceutiques
WO2004041153A3 (fr) Composition pharmaceutique comprenant de faibles dosages de desmopressine
ATE317702T1 (de) Rezeptorspezifischer transepithelialtransport von therapuetica
BRPI0407648A (pt) uso de uma proteìna ligante sìtio-especìfica ativa juntamente com um vetor terapêutico codificando uma proteìna para manufatura de um medicamente
WO2004084950A3 (fr) Procedes et compositions de ciblage cellulaire
DE69412593D1 (de) Anthrax-toxin-fusionsproteine und deren verwendungen
WO2002032893A3 (fr) Nouveaux composes non imidazole
WO2004043363A8 (fr) Preparations liposomales d'agents pharmaceutiques stabilisees par des proteines
WO2006020580A3 (fr) Variants de polypeptides synthetiques hyperglycosyles resistants a la protease, formulations orales et leurs procedes d'utilisation
WO2003033027A3 (fr) Dendrimeres utilises pour une administration ciblee
WO2006004959A3 (fr) Peg-interferon alpha-1b
DE60031504D1 (de) Fluticasonpropionat arzneizubereitung
WO2002055098A3 (fr) Methode pour conferer un temps de latence a des substances pharmaceutiquement actives
HK1042234A1 (zh) 向肺部施加乾粉配方以治疗不育症
MXPA04005053A (es) Metodos y composiciones para tratar lesiones del epitelio respiratorio.
WO2006041641A3 (fr) Agents therapeutiques a toxicite reduite
WO2007044809A3 (fr) Préparations pharmaceutiques basées sur une toxine botulique sans albumine et contenant une hyaluronidase, et méthodes d'emploi
CA2558212A1 (fr) Therapie antivirus pour le traitement de maladies respiratoires
AU2001276831A1 (en) Delivery vehicle composition and methods for delivering antigens and other drugs
WO2008028934A8 (fr) Conjugués de disorazoles et leurs dérivés avec des molécules se fixant à des cellules, nouveaux dérivés de disorazole et procédés de fabrication et d'utilisation de ces conjugués et dérivés
WO2004033705A3 (fr) Antagonistes des interferons viraux et utilisations de ceux-ci

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2491129

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003232081

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004519544

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003762973

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003762973

Country of ref document: EP